Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Recentin

(cediranib maleate)

Phase 3Small molecule

NNational Cancer Institute (NCI)

Cediranib maleate is used to treat certain types of cancer, particularly ovarian cancer when used in combination with other chemotherapy drugs. It works by blocking the growth of new blood vessels that tumors need to survive and grow.[1] Recentin is currently being investigated across 36 indications[3], with its most advanced program in Phase 3.[1]

Recentin is one of 774 small molecule programs targeting Clear Cell Renal Carcinoma. It is currently in Phase 3.

36

Indications

50

Total Trials

10

Active Trials

773

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clear Cell Renal CarcinomaActive, not recruiting

Kidney CancerActive, not recruiting

Lung CancerActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

Anaplastic AstrocytomaActive, not recruiting

MesotheliomaActive, not recruiting

Adult Hepatocellular CarcinomaActive, not recruiting

Malignant MesotheliomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Uveal MelanomaActive, not recruiting

Clear Cell Renal CarcinomaPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

Malignant Pleural MesotheliomaPhase 2

Active, not recruiting

Anaplastic AstrocytomaPhase 1

Active, not recruiting

MesotheliomaPhase 2

Active, not recruiting

Adult Hepatocellular CarcinomaPhase 2

Active, not recruiting

Malignant MesotheliomaPhase 2

Active, not recruiting

Triple-Negative Breast CancerPhase 1/Phase 2

Active, not recruiting

Uveal MelanomaPhase 2

Active, not recruiting

Showing 10 of 36 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Recentin

NNational Cancer Institute (NCI)

Tecentriq

Avastin

BBio-Thera Solutions

Cymbalta

Alnylam Pharmaceuticals

MS Contin

Voltaren

Tricor

Feraheme

AAzurity Pharmaceuticals

Zoladex

Luye Pharma Group Ltd.

Beta Blocker

WWeill Medical College of Cornell University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Recurrent Glioblastoma

NCT02974621

Q4 2026

Phase 2Active, not recruiting

Ovarian Cancer

NCT02345265

Phase 1/2Active, not recruiting

Triple-Negative Breast Cancer

NCT01116648

Q1 2027

Phase 2Active, not recruiting

Endometrial Adenocarcinoma

NCT03660826

Phase 3Active, not recruiting

Fallopian Tube Clear Cell Adenocarcinoma

NCT02446600

PreclinicalActive, not recruiting

Fallopian Tube Clear Cell Adenocarcinoma

NCT02502266

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00343408·31 enrolled

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·NNCIC Clinical Trials Group·Phase 2/3·NCT00245154·296 enrolled

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00937482·18 enrolled

Show 3 more trials

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00410904·60 enrolled

Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00795340·306 enrolled

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00326599·101 enrolled

Glioblastoma4 trials

Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Terminated·UUniversity College, London·Phase 2·NCT01310855·38 enrolled

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00979862·47 enrolled

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01062425·261 enrolled

Show 1 more trial

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00662506·46 enrolled

Fallopian Tube Cancer2 trials

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00278343·74 enrolled

AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00275028·47 enrolled

Malignant Pleural Mesothelioma2 trials

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT01064648·117 enrolled

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00243074·54 enrolled

Breast Cancer2 trials

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00244881·26 enrolled

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Completed·NNational Cancer Institute (NCI)·N/A·NCT00310089·33 enrolled

30 more indications

Liver Cancer2 trials

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00238394·44 enrolled

AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00427973·17 enrolled

Small Cell Lung Cancer2 trials

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00245063·25 enrolled

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02899728·9 enrolled

Kidney Cancer2 trials

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00227760·44 enrolled

AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00303862·10 enrolled

Fallopian Tube Clear Cell Adenocarcinoma2 trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02446600·579 enrolled

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02502266·582 enrolled

Melanoma1 trial

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00243061·24 enrolled

Advanced Solid Tumors1 trial

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02498613·122 enrolled

Chronic Lymphocytic Leukemia1 trial

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00321724·35 enrolled

Uveal Melanoma1 trial

Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

Withdrawn·GGrupo Español Multidisciplinar de Melanoma·Phase 2·NCT04184518

Solid Malignancies1 trial

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01364051·19 enrolled

Patients With Advanced Solid Tumors1 trial

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01131234·20 enrolled

Myelodysplastic Syndrome1 trial

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00475150·39 enrolled

Cervical Cancer1 trial

Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery

Completed·UUniversity of Glasgow·Phase 2·NCT01229930·130 enrolled

Colorectal Cancer1 trial

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00107250·50 enrolled

Endometrial Cancer1 trial

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01132820·53 enrolled

Metastatic Prostate Cancer1 trial

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00527124·57 enrolled

Neurofibromatosis Type 11 trial

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00326872·26 enrolled

Anaplastic Astrocytoma1 trial

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00458731·57 enrolled

Biliary Cancer1 trial

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01229111·14 enrolled

Metastatic Head and Neck Cancer1 trial

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00458978·6 enrolled

Metastatic Colorectal Cancer1 trial

Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00588900·5 enrolled

Ovarian Cancer1 trial

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02345265·70 enrolled

Triple-Negative Breast Cancer1 trial

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT01116648·155 enrolled

Treatment1 trial

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01260688·22 enrolled

Glioblastoma Multiforme1 trial

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00305656·31 enrolled

Thyroid Cancer1 trial

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01208051·127 enrolled

Malignant Mesothelioma1 trial

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00309946·51 enrolled

Refractory1 trial

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00326664·55 enrolled

Fallopian Tube Mucinous Adenocarcinoma1 trial

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04739800·120 enrolled

Recurrent Glioblastoma1 trial

A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02974621·70 enrolled

Endometrial Adenocarcinoma1 trial

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03660826·288 enrolled

Sources

References

[1]
ClinicalTrials.gov — 50 trial records for cediranib maleate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cediranib maleate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cediranib maleate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

Related News